LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Home・Akciju saraksts・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Slēgts

1.1 -1.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.07

Max

1.1400000000000001

Galvenie mērījumi
By Trading Economics
Ienākumi	1.7M -5.1M
Pārdošana	90K 90K
Peļņas marža	-5,701.111
Darbinieki	25
EBITDA	2.6M -4.9M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 27. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-6.9M 35M
Iepriekšējā atvēršanas cena	2.89
Iepriekšējā slēgšanas cena	1.1

Actinium Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. marts 22:51 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026. g. 18. marts 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026. g. 18. marts 20:31 UTC

Peļņas

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026. g. 18. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026. g. 18. marts 23:31 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery -- Market Talk

2026. g. 18. marts 22:49 UTC

Tirgus saruna

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026. g. 18. marts 22:41 UTC

Tirgus saruna

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026. g. 18. marts 22:36 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026. g. 18. marts 22:24 UTC

Peļņas

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026. g. 18. marts 21:58 UTC

Peļņas

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026. g. 18. marts 21:40 UTC

Tirgus saruna

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026. g. 18. marts 21:16 UTC

Tirgus saruna

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026. g. 18. marts 21:00 UTC

Galvenie ziņu notikumi

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026. g. 18. marts 20:58 UTC

Peļņas

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026. g. 18. marts 20:41 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:29 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:25 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:17 UTC

Peļņas

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026. g. 18. marts 20:14 UTC

Tirgus saruna

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026. g. 18. marts 20:09 UTC

Peļņas

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026. g. 18. marts 20:07 UTC

Peļņas

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026. g. 18. marts 20:06 UTC

Peļņas

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026. g. 18. marts 20:03 UTC

Peļņas

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Salīdzinājums

Cenas izmaiņa

Actinium Pharmaceuticals Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Actinium Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.